Association between the detection of EGFR mutations and the efficacy of EGFR-tyrosine kinase inhibitors in lung cancer patients
博士 === 國立中興大學 === 生物醫學研究所 === 103 === Lung cancer is the leading cause of cancer-related death both worldwide and in Taiwan. In a recent decade, epidermal growth factor receptor (EGFR)-targeted therapy has emerged as a novel and effective strategy in lung cancer management. Activating mutations...
Main Authors: | Jeng-Sen Tseng, 曾政森 |
---|---|
Other Authors: | Gee-Chen Chang |
Format: | Others |
Language: | zh-TW |
Published: |
2015
|
Online Access: | http://ndltd.ncl.edu.tw/handle/21505094630515665440 |
Similar Items
-
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01) -
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
by: Daniel B Costa, et al.
Published: (2007-10-01) -
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019-11-01) -
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
by: Shang-Gin Wu, et al.
Published: (2017-07-01) -
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang J, et al.
Published: (2016-06-01)